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Background: Numerous randomized trials have demonstrated that treatment with a statin reduces the risk of major cardiovascular events (MCE). 
We sought to quantitatively estimate the potential pleiotropic effect of statins by estimating the magnitude of this clinical benefit not related to the 
low-density lipoprotein cholesterol (LDL-C) lowering effects of statins.
Methods: We conducted a meta-regression analysis of statin trials to estimate the effect of statin therapy on the risk of MCE per mmol/L change 
in LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG). We used the constant term in the meta-regression equation to estimate 
the potential pleiotropic effect of statins not related to changes in LDL-C, HDL-C or TG.
Results: In a meta-regression analysis of 26 statin trials involving 169,138 participants (Table), treatment with a statin resulted in an 18% 
reduction in the risk of MCE per mmol/L reduction in LDL-C (RR: 0.82, 95%CI: 0.73-0.91), with no evidence of a significant additional pleiotropic 
effect (RR: 0.98, 95%CI: 0.89-1.09). In analyses that controlled for changes in HDL-C and TG, the effect of statin therapy per mmol/L reduction in 
LDL-C remained unchanged (RR: 0.83, 95%CI: 0.70-0.98), with no evidence for an additional pleiotropic effect (RR: 1.00, 95%CI: 0.88-1.13).
Conclusion: The clinical benefit of statin therapy appears to be mediated almost entirely by reductions in LDL-C with no evidence of a significant 
additional potential pleiotropic effect. 
RR (95% CI)
Model
Constant
(pleiotropic effect)
Change in
LDL-C
Change in
HDL-C
Change in
TG
1 0.98 (0.89-1.09) 0.82 (0.73-0.91)
2 0.84 (0.79-0.89) 0.34 (0.07-1.56)
3 0.99 (0.88-1.10) 0.81 (0.71-0.93) 1.11 (0.27-4.67)
4 1.00 (0.88-1.13) 0.83 (0.70-0.98) 0.94 (0.18-5.04) 0.91 (0.53-1.54)
